title: The incidence of malignancy in heart transplant recipients.
abstract: OBJECTIVE
  219 heart transplant recipients with survival over 3 months were retro- and prospectively analysed for the incidence of primary neoplasms. Patients received immunosuppressive drugs (cyclosporine A, azathioprine, steroids) with a 4-5 days induction course of Rabbit Anti-Thymocyte Immunoglobulin (RATG) or monoclonal antibodies induction /OKT3/ in some cases. Anti-rejection treatment consisted of pulse doses of methyloprednisolon or RATG.
  
  
  RESULTS
  9 cases of malignancy (4.1%) with one case of pre-malignant liver condition (dysplasia gigantocellulare, 0.45%) were found (8M; 1F; age: 45-67 y.o., x57.7). Symptoms of neoplasms occurred 7-79 months (x31.4) postoperatively. Skin carcinomas: planoepitheliale, spinocellulare, soft tissue neoplasms/mesenchymal sarcoma, larynx Ca planoepitheliale, lung: adenocarcinoma and Ca microcellulare, kidney Ca clarocellulare and post transplant non-Hodgkin lymphoma were diagnosed. Chemo- and radiotherapy, surgery and reduction of immunosuppression did not change the outcome of malignancy in 6 pts.; (regression-1 pt was., remission-2 pts). Patients died 7-86 months after Htx (x41), 4-25 mos. (x12.5) after suffering from first symptoms and 0-10 months (x4.9) after pathology-based diagnosis of neoplasm.
  
  
  CONCLUSIONS
  Heart transplant recipients have an increased risk of carcinogenesis. The incidence of malignancies in the studied group is similar or even lower than in other reports.
authors.affiliation: Department of Cardiac and Vascular Surgery, Jagiellonian University, Cracow, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Garlicki
authors.forename: K
authors.initials: K
authors.lastname: Wierzbicki
authors.forename: P
authors.initials: P
authors.lastname: Przybyłowski
authors.forename: D
authors.initials: D
authors.lastname: Drop
authors.forename: M
authors.initials: M
authors.lastname: Biernat
authors.forename: P
authors.initials: P
authors.lastname: Rudziński
authors.forename: B
authors.initials: B
authors.lastname: Olszewska
authors.forename: A
authors.initials: A
authors.lastname: Dziatkowiak
mesh_terms: D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D011044:Poland / Q000453:epidemiology; D011446:Prospective Studies; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine